RESCRIPTOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESCRIPTOR is an oral small-molecule antiretroviral approved in 1997 for HIV-1 infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks viral replication by inhibiting the HIV-1 reverse transcriptase enzyme. The drug is administered as a tablet and represents an older class within the HIV treatment armamentarium.
LOE Approaching
As LOE approaches, RESCRIPTOR teams are consolidating; expect focus on generic transition planning and risk mitigation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Started Dec 2003
3 enrolled
HIV-1 Infection
Career Relevance
RESCRIPTOR offers limited career growth due to its LOE-approaching status and zero linked job openings. Positions on this brand are in managed-decline mode, suitable only for professionals seeking end-of-lifecycle expertise or interim roles before reassignment.
Brand Manager (transition planning)
Worked on RESCRIPTOR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.